The presently disclosed subject matter relates to a composition and method of using the composition for oral delivery of a bioactive agent to a subject. More particularly, the presently disclosed subject matter relates to a composition comprising an effective amount of at least one bioactive agent layered over a substrate and a method of reducing zoonotic infectious disease by administering the composition to a subject. The presently disclosed subject matter further relates to a method of preparing the composition.

Conditionally replicating recombinant cells, compositions and vaccines having the cells, and methods of using the cells, are provided.

The present disclosure is directed to compositions and methods useful for treating, as well as vaccinating against, SARS-CoV-2 viral infections, including SARS-CoV-2 variant viral infections.

Disclosed are immunotherapeutic compositions and the concurrent use of combinations of such compositions for the improved induction of therapeutic immune responses and/or for the prevention, amelioration and/or treatment of disease, including, but not limited to, cancer and infectious disease.

The invention provides a bacterium containing a polynucleotide comprising a nucleic acid encoding a heterologous antigen, as well as fusion protein partners. Also provided are vectors for mediating site-specific recombination and vectors comprising removable antibiotic resistance genes.

The invention features probiotic bacteria expressing Clostridium difficile SlpA, or fragment thereof, and its use for the treatment or prevention of Clostridium difficile infection and gut colonization.

Contemplated cancer therapies comprise co-administration of aldoxorubicin with an immune therapeutic composition that preferably comprises a vaccine component and a cytotoxic cell component.

Disclosed in the present disclosure are a recombinant human papillomavirus vaccine composition and a use thereof. Compared with other combinations of antigens and adjuvants, the new vaccine composition provided in the present invention has a more beneficial immune effect.

Cancer is treated via a coordinated treatment regimen that use various compounds and compositions that employ a combination vaccination together with immune modulatory treatment and biasing of an immune response towards a Th1 profile.

The disclosure provides native outer membrane vesicle (NOMV) vaccines containing a coronavirus receptor binding domain (RBD) modified to be a lipoprotein. Also provided are compositions comprising a meningococcal strain having a plasmid-borne gene encoding the SARS-CoV-2 RBD modified to be a lipoprotein. Also provided are a meningococcal strain and a NOMV vaccine containing a plasmid coding for the SARS-CoV-2 RBD with a promoter/enhancer and polyA sequence that provide for expression of the RBD in mammalian cells.